Keymed Biosciences, Inc. (HK:2162) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Keymed Biosciences Inc. has announced that China’s National Medical Products Administration approved its drug Stapokibart for treating chronic rhinosinusitis with nasal polyposis. The phase III clinical trial showed significant improvements in nasal polyp size and congestion, with a favorable safety profile. This approval marks a significant step for Keymed, showcasing its potential in the pharmaceutical market.
For further insights into HK:2162 stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue